A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial

BACKGROUND: Cardiometabolic disease in transgender women (TW) is affected by gender-affirming hormonal therapies (GAHTs), HIV, and antiretroviral therapy (ART). We evaluated the 48-week safety/tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs continued ART in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lake, Jordan E, Hyatt, Ana N, Feng, Han, Debroy, Paula, Kettelhut, Aaren, Miao, Hongyu, Peng, Liming, Bhasin, Shalender, Bell, Susan, Rianon, Nahid, Brown, Todd T, Funderburg, Nicholas T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122488/
https://www.ncbi.nlm.nih.gov/pubmed/37096146
http://dx.doi.org/10.1093/ofid/ofad178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122488/
https://www.ncbi.nlm.nih.gov/pubmed/37096146
http://dx.doi.org/10.1093/ofid/ofad178

Ejemplares similares